sector medic suppli devic
messag turn underwhelm modest miss
top bottom line earn qualiti also low lower tax rate paper
ebita miss despit underwhelm start year manag maintain
sale forecast even account anticip coronaviru
headwind rais ep forecast lower interest/tax expens see
one best posit med-tech compani weather protract coronavirus-
relat slowdown posit could support stock near-term absent
howev see share rel fulli valu current level
turn underwhelm first quarter revenu cc
miss consensu adjust ep yoy came
street expect ebita margin came light estim lower
expect tax rate ad earn top line momentum slow across
busi segment cc csi cc deceler
respect rel one-tim item contribut slower
growth case howev japanes contact len sale feel hangov effect
septemb vat tax increas fertil experienc temporari shipment delay
posit note manag expect impact coronaviru
limit project revenu headwind
csi sale chines hospit primarili ortho-k lens fertil product
remain signific pressur howev compani yet see materi impact
outsid china although guidanc assum lost chines sale
recoup later year ceo al white optimist portion could
meantim improv myday capac recent contract win fertil busi
expect make differ allow maintain revenu
outlook cc meanwhil manag rais ep guidanc
yoy driven lower interest expens
favor tax rate adjust ultim extent disrupt caus
remain difficult project believ initi assess uniqu
characterist contact len market patient obtain much product
mail posit compani weather storm better mani tradit
med-tech compani someth think could buoy stock near-term
turn back quarter coopervis sale cc came
consensu categori perspect major weak came
non single-us sphere cc miss single-
use sphere cc miss shortfal partial off-set
toric cc multifoc cc beat
respect particularli encourag perform toric
hamper myday capac constraint quarter dynam
improv go forward manag note product alreadi increas
geograph basi growth pace strong gain america cc
solid perform emea cc meanwhil asia pacif weak quarter
due hangov effect recent japan vat tax increas myday constraint
headwind behind manag expect asia pacif busi
return growth even account anticip impact coronavirus-
relat disrupt reacceler double-digit growth back half year
elsewher estim silicon hydrogel len sale rose
forecast growth driven compani daili sih lens clariti
myday yoy ex-fx meanwhil compani extend wear
sih portfolio biofin avaira grew cc driven weak
asia pacif continu next page
page analyst certif import disclosur
wrap maintain misight forecast misight gener
sale yoy slightli estim still
expect number reach contribut follow
initi domest launch month look ahead compani reiter forecast
global misight sale respect regard
 launch complet kol launch januari finish train sale rep
februari recent invit doctor particip misight educ
certif program held seven top optometri school call
manag note earli feedback misight extrem posit
encourag sign compani aim demonstr treatment
standard care young patient myopia kid world-wide
treat misight date last quarter
market perspect estim global len sale rose cc calendar
four major manufactur combin sale
yoy report basi bhc
gain share sequenti alc cede ground vs
yoy basi alc modest share donor
bhc beneficiari loss sharp market
deceler would chalk almost entir japan vat tax issu
averag constant currenc growth back half year essenti match
saw vs contact len market remain healthi overal
long-term trend increas daili use silicon hydrogel adopt continu drive
posit mix top solid underli volum gain continu outperform
backdrop compani trail underli growth rate
stand vs competitor see figur
compani report guggenheim secur llc estim
compani report guggenheim secur llc estim
expect anoth year cc market gain believ cooper
remain well-posit continu take share model call compani
pick anoth top gain increas daili sih
competit dynam keep eye move forward howev alcon
bausch aqualox expect ramp presenc next
sever quarter extent alcon drive acceler contact len
growth particular interest biggest laggard space
past year
page analyst certif import disclosur
side busi coopersurg revenu cc
match consensu paragard sale beat flat yoy follow
signific buy-in activ last quarter ahead price increas manag continu
target mid-singl digit growth paragard year buoy new dtc commerci
campaign underway overal offic surgic product sale rose cc
meanwhil fertil revenu ex-fx shipment delay hamper
perform look ahead manag expect stronger fertil
shipment recogn growth acceler back half year
driven recent contract win
incom statement lower expect tax rate enough off-set
elev sg spend fiscal gross margin
yoy still ahead consensu off-set elev expens
sg spend rose yoy sale came street
expect meanwhil spend increas yoy sale line
consensu collect result ebita margin
yoy street estim shortfal partial off-set lower
expect tax ad ep manag also lower full year tax rate
guidanc along reduc interest expens coo
debt float rate drove compani increas ep outlook
adjust estim maintain neutral model call post
ep total revenu cc compar
previou estim respect believ could
seen rel safe near-term investor grappl ultim
coronaviru fallout continu expect impact broader sector transient
natur meantim see share rel fulli valu current level
compar large-cap med-tech group ntm ep vs result
maintain neutral rate
page analyst certif import disclosur
straddl line healthcar consum product contact
len women health busi coopervis portfolio uniqu posit take
advantag two tailwind drive contact len market growth today shift
premium len materi particular silicon hydrogel increas popular
daili dispos lens recent year leverag broadest daili sih
offer market lead posit monthli sih categori continu
long histori above-market growth compani captur averag
market share per year sinc expect gain moder go forward
backdrop competit contact len market believ cooper
remain well posit sustain growth
elsewher paragard deal ad scale increment growth
coopersurg women health franchis often overlook investor csi
account overal revenu
growth fuel primarili compani invest
half dozen deal build lead posit ivf genet test market
follow acquisit paragard intrauterin devic
believ long-term fundament market appeal see grow
scale csi neg broader invest case complic stori
believ investor would prefer look sole contact len play
share current trade ntm ep ntm ebitda
repres premium large-cap med-tech group averag price-to-earnings
large-cap group would seem argu slight premium valuat
compani long-term bottom line growth trajectori essenti line
group averag also view cooper outsiz exposur currenc
swing rise interest rate consum categori believ could prove
highli cyclic next econom downturn argument multipl
expans result maintain neutral rate
upsid risk rate includ faster expect contact len market growth due
rise sih penetr daili len adopt increas share gain
busi better expect growth/accret paragard
downsid risk rate includ better anticip traction competit
contact len launch weaken macroeconom backdrop put pressur
cooper busi see discretionari med-tech market
potenti exposur strong dollar rise interest rate
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
compani report guggenheim secur llc estim
page analyst certif import disclosur
